Bilateral improvement in visual acuity from a unilateral injection of gene therapy – consistent with REVERSE trial findings Significant improvement against visual acuity nadir Paris, France, January 13, 2021, 7:30 am CET – GenSight Biologics (Euronext: SIGHT, I... read more

PHILADELPHIA, Jan. 7, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that it has completed its Series B equity financing providing for gross proceeds of $47 million, bringing CARISMA'... read more

-CAHmelia Adult Classic CAH Program Underway in U.S. and Europe- -Initiation of Phase 2 Pediatric Classic CAH Program Anticipated in Second Half of 2021- -Initiation of Phase 2 Polycystic Ovary Syndrome Program Anticipated in Second Half of 2021- -New Patent Issuance Extends Tildacerfont Patent E... read more

 Expects to Report KEVEYIS® (dichlorphenamide) Fourth Quarter 2020 Revenue of Approximately $8.2 Million and Full-Year 2020 Revenue of Approximately $30.7 Million, a 41.5 Percent Increase over 2019 Revenue of $ $21.7 Million ~ ~ Targets Full-Year 2021 KEVEYIS® (dichlorphenamide) Revenue G... read more

COVID-19 have caused delays to submission and processing of the regulatory application to initiate clinical development in China Due to the unforeseen delays, Targovax has extended the term of IOvaxis´s license option by 3 months, otherwise the agreement remains unchanged Oslo, Norway 6 ... read more